Latest Headlines

Latest Headlines

Buzz: Is Bayer looking to buy Onyx Pharma?

Reuters reported today that Bayer is looking to close a multibillion-euro acquisition deal, quoting sources who say that an announcement could be "imminent."

Piramal lays claim to a late-stage imaging rival for Lilly's Alzheimer's agent

Piramal wasn't saying just how much it paid for the portfolio, but rather breezily claimed that the market for such Alzheimer's imaging agents could amount to $1.5 billion.

Bloomberg: Bayer to pay $110 million to get out from under 500 Yaz lawsuits

Three months of negotiations have apparently resulted in Bayer deciding that claims against its Yasmin line of birth control are worth about $220,000 each.

FDA adds clotting data to Bayer's Yaz, Yasmin

To make sure doctors and patients are aware of the potential dangers, the pills' labels will now include study data suggesting as much as a threefold increase in clotting risk.

Judge lets sex-bias suit against Bayer go ahead

Bayer failed to stop 8 women from seeking class-action status for their sex-discrimination claims against the company.

Bayer bolsters blockbuster case for regorafenib with new PhIII data

Bayer has racked up a fresh set of preliminary late-stage data that will bolster its plans to market regorafenib for a range of cancers.

Bayer gets positive ruling from NICE on Xarelto

NICE has recommended the drug for stroke and embolisms in draft guidance, and final guidance may come in April.

U.S. questions India's IP regime after Nexavar move

Is intellectual property safe in India? That's the question drugmakers--and now U.S. officials--are asking.

Roche to offer cancer drugs in India at deep discounts

Roche has stepped up with plans to slash the cost of Herceptin and MabThera.

Bayer, others fined $15.9M by Romanian competition authority

The Romanian Competition Council has wrapped up an ongoing investigation into alleged antitrust practices by Bayer ($BAY), Sintofarm and 9 distributors. The result: a combined €12 million in fines the companies must pay.